JAN (NYSE:JAN) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst sentiment is moderately bullish: Seventeen analysts give JAN an average “Moderate Buy” rating, including 12 buys, four holds, and one strong buy. The average 12-month price target is $32.44.
• JAN opened at $28.74, down 1.1%, after recently trading between $22.76 and $32.83. Its latest quarter beat revenue expectations with $216.46 million, but EPS of $0.05 missed consensus by $0.18.
• The company announced a $0.0475 monthly dividend, equivalent to $0.57 annually and a 2.0% yield. Institutional investors have recently established new positions, though institutions own only 6.27% of JAN’s shares.

Shares of JAN (NYSE:JAN - Get Free Report) have received an average recommendation of "Moderate Buy" from the seventeen analysts that are presently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $32.44.

Several research firms recently commented on JAN. Barclays boosted their price target on JAN from $33.00 to $34.00 and gave the stock an "overweight" rating in a research report on Monday, August 31st. Cantor Fitzgerald boosted their target price on shares of JAN from $30.00 to $34.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Scotiabank upped their target price on shares of JAN from $31.00 to $33.00 and gave the company a "sector outperform" rating in a research note on Thursday, September 17th. Weiss Ratings initiated coverage on shares of JAN in a report on Thursday, August 6th. They set a "hold (c-)" rating for the company. Finally, UBS Group set a $29.00 price target on shares of JAN in a research note on Thursday, June 18th.

JAN Trading Down 1.1%

NYSE JAN opened at $28.74 on Tuesday. JAN has a 1-year low of $22.76 and a 1-year high of $32.83. The company has a 50-day moving average price of $30.38.

JAN (NYSE:JAN - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.23 by ($0.18). The firm had revenue of $216.46 million for the quarter, compared to analyst estimates of $203.32 million. The company's quarterly revenue was up 45.4% on a year-over-year basis. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. Sell-side analysts expect that JAN will post 0.97 EPS for the current fiscal year.

JAN Dividend Announcement

The firm also recently announced a monthly dividend, which will be paid on Tuesday, December 29th. Stockholders of record on Friday, December 18th will be paid a dividend of $0.0475 per share. The ex-dividend date is Friday, December 18th. This represents a $0.57 annualized dividend and a dividend yield of 2.0%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of JAN. Engineers Gate Manager LP acquired a new stake in JAN during the 2nd quarter valued at approximately $15,274,000. Wellington Management Group LLP acquired a new position in shares of JAN in the 2nd quarter valued at approximately $8,739,000. WINTON GROUP Ltd acquired a new position in shares of JAN in the 2nd quarter valued at approximately $2,985,000. Readystate Asset Management LP purchased a new position in shares of JAN during the 2nd quarter valued at approximately $1,724,000. Finally, Greenland Capital Management LP acquired a new stake in shares of JAN during the second quarter worth approximately $575,000. Hedge funds and other institutional investors own 6.27% of the company's stock.

JAN Company Profile

JanOne Inc NYSE: JAN is a publicly traded company focused on addressing the opioid crisis through the development and commercialization of solutions intended to improve the treatment and prevention of opioid use disorder. The company has described its mission as combining business, technology and scientific initiatives to help reduce opioid-related harm.

JanOne's activities have included biotechnology and pharmaceutical-development initiatives, as well as investments in technologies and businesses connected with healthcare and financial services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.